Lanreotide
| Code | Size | Price |
|---|
| TAR-T20534-200mg | 200mg | £992.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.
CAS:
108736-35-2
Formula:
C54H69N11O10S2
Molecular Weight:
1096.33
Purity:
0.98
SMILES:
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@H](N)Cc1ccc2ccccc2c1
References
1. Caplin ME, Pavel M, ?wik?a JB, Phan AT, Raderer M, Sedl??kov? E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. PubMed PMID: 25014687.
2. Burness CB, Dhillon S, Keam SJ. Lanreotide autogel(?): a review of its use in the treatment of patients with acromegaly. Drugs. 2014 Sep;74(14):1673-91. doi: 10.1007/s40265-014-0283-8. Review. PubMed PMID: 25193626.
3. Capdevila J, Sevilla I, Alonso V, Ant?n Aparicio L, Jim?nez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso L?jara JD, Barriuso J, Castellano D, Medina J, L?pez C, Segura ?, Carrera S, Crespo G, Fuster J, Munarriz J, Garc?a Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6. PubMed PMID: 26138480; PubMed Central PMCID: PMC4490650.
4. Zheng N, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang K, Li J, Zhang Q. Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors. J Drug Target. 2015 Jan;23(1):67-78. doi: 10.3109/1061186X.2014.954118. Epub 2014 Nov 4. PubMed PMID: 25366085.